After 19 years with the US healthcare giant Johnson & Johnson (NYSE: JNJ), Dominic Caruso, executive vice president, chief financial officer, has elected to retire in September 2018. Mr Caruso was named CFO in 2007, and served as CFO longer than anyone in the company’s 132- year history.
"During his nearly 12 years as CFO, Dominic provided Credo-based leadership and financial stewardship through the economic downturn and was instrumental in helping the company deliver significant gains over the past five years," said Alex Gorsky, chairman and chief executive of Johnson & Johnson.
Under Mr Caruso’s leadership, the company completed three of its largest acquisitions: Actelion, Synthes and Pfizer Consumer Health. He was also instrumental in driving growth and capital allocation strategies that led Johnson & Johnson to exceed our competitor composite, as well as most major indices, for total shareholder return in 2017 and over the last three-, five-, ten- and twenty-year periods.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze